Q-omics provides the consensus-scored RPL13AP19 profile across patient tissues and cancer cell-line models. RPL13AP19 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RPL13AP19 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, RPL13AP19 RNA expression shows 13,640 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight STAD, KIRC, and LSCC as cancer lineages where RPL13AP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL13AP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL13AP19 survival associations across molecular data types. RPL13AP19 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL13AP19 RNA expression–survival associations across cancer types. High RPL13AP19 expression shows unfavorable associations in STAD, SARC and BRCA, but favorable associations in BLCA, SKCM and CESC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify STAD as the clearest survival context for RPL13AP19 RNA expression.
This table summarizes RPL13AP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL13AP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL13AP19 shows higher tumor expression in KIRC, LIHC and HNSC. The KIRC box plot shows higher RPL13AP19 RNA expression in tumor versus normal tissue (log2 FC = +0.061, t-test p = .002).
This table shows molecular features associated with RPL13AP19 in patient tissues and cancer cell lines. In patient samples, RPL13AP19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
